BECAIT Trial: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==BECAIT Trial== ===Objective=== To evaluate if bezafibrate could slow the progression of coronary stenoses in dyslipidemic mal...")
 
No edit summary
Line 3: Line 3:


{{CMG}}
{{CMG}}
==BECAIT Trial==
==Objective==
===Objective===
To evaluate if bezafibrate could slow the progression of coronary stenoses in dyslipidemic male survivors of myocardial infarction who were younger than 45 years at the time of the event.
To evaluate if bezafibrate could slow the progression of coronary stenoses in dyslipidemic male survivors of myocardial infarction who were younger than 45 years at the time of the event.


===Method===
==Method==
The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a randomized, double-blinded, placebo-controlled trial over 5 years to assess the angiographic benefits of bezafibrate retard (400 mg a day) in 92 young (45 yrs), male, post-[[myocardial infarction]] (post-MI) patients with [[dyslipidemia]] (fasting serum [[cholesterol]] concentration above 240 mg/dL and [[triglyceride]] concentration above 141 mg/dL).
The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a randomized, double-blinded, placebo-controlled trial over 5 years to assess the angiographic benefits of bezafibrate retard (400 mg a day) in 92 young (45 yrs), male, post-[[myocardial infarction]] (post-MI) patients with [[dyslipidemia]] (fasting serum [[cholesterol]] concentration above 240 mg/dL and [[triglyceride]] concentration above 141 mg/dL).


===Results===
==Results==
* [[Bezafibrate]] reduced the levels of LDL-C and triglycerides by 53% and 46% respectively
* [[Bezafibrate]] reduced the levels of LDL-C and triglycerides by 53% and 46% respectively
* Plasma apolipoprotein (apo) B levels reduced by 9%
* Plasma apolipoprotein (apo) B levels reduced by 9%
* [[HDL]]3 levels rose by 9%
* [[HDL]]3 levels rose by 9%


===Conclusion===
==Conclusion==
The effect of bezafibrate on progression of focal coronary atherosclerosis could be at least partly attributed to a rise in HDL3 cholesterol and a decrease in the total number of apo B-containing lipoproteins. Treatment with bezafibrate also significantly reduced the levels of [[insulin-like growth factor]] (IGF-1) which is one other factor associated with disease progression.<ref name="pmid9822092">{{cite journal |author=Ruotolo G, Ericsson CG, Tettamanti C, ''et al.'' |title=Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) |journal=J. Am. Coll. Cardiol. |volume=32 |issue=6 |pages=1648–56 |year=1998 |month=November |pmid=9822092 |doi= |url=}}</ref><ref name="pmid7555614">{{cite journal |author=de Faire U, Ericsson CG, Hamsten A, Nilsson J |title=Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) |journal=Drugs Exp Clin Res |volume=21 |issue=3 |pages=105–24 |year=1995 |pmid=7555614 |doi= |url=}}</ref><ref name="pmid8622389">{{cite journal |author=Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U |title=Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients |journal=Lancet |volume=347 |issue=9005 |pages=849–53 |year=1996 |month=March |pmid=8622389 |doi= |url=}}</ref><ref name="pmid9717064">{{cite journal |author=Ericsson CG |title=Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress |journal=Eur. Heart J. |volume=19 Suppl H |issue= |pages=H37–41 |year=1998 |month=July |pmid=9717064 |doi= |url=}}</ref>
The effect of bezafibrate on progression of focal coronary atherosclerosis could be at least partly attributed to a rise in HDL3 cholesterol and a decrease in the total number of apo B-containing lipoproteins. Treatment with bezafibrate also significantly reduced the levels of [[insulin-like growth factor]] (IGF-1) which is one other factor associated with disease progression.<ref name="pmid9822092">{{cite journal |author=Ruotolo G, Ericsson CG, Tettamanti C, ''et al.'' |title=Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) |journal=J. Am. Coll. Cardiol. |volume=32 |issue=6 |pages=1648–56 |year=1998 |month=November |pmid=9822092 |doi= |url=}}</ref><ref name="pmid7555614">{{cite journal |author=de Faire U, Ericsson CG, Hamsten A, Nilsson J |title=Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) |journal=Drugs Exp Clin Res |volume=21 |issue=3 |pages=105–24 |year=1995 |pmid=7555614 |doi= |url=}}</ref><ref name="pmid8622389">{{cite journal |author=Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U |title=Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients |journal=Lancet |volume=347 |issue=9005 |pages=849–53 |year=1996 |month=March |pmid=8622389 |doi= |url=}}</ref><ref name="pmid9717064">{{cite journal |author=Ericsson CG |title=Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress |journal=Eur. Heart J. |volume=19 Suppl H |issue= |pages=H37–41 |year=1998 |month=July |pmid=9717064 |doi= |url=}}</ref>


Line 24: Line 23:
[[Category:Lipopedia]]
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]

Revision as of 23:20, 17 September 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

BECAIT Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of BECAIT Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on BECAIT Trial

CDC on BECAIT Trial

BECAIT Trial in the news

Blogs on BECAIT Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for BECAIT Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To evaluate if bezafibrate could slow the progression of coronary stenoses in dyslipidemic male survivors of myocardial infarction who were younger than 45 years at the time of the event.

Method

The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a randomized, double-blinded, placebo-controlled trial over 5 years to assess the angiographic benefits of bezafibrate retard (400 mg a day) in 92 young (45 yrs), male, post-myocardial infarction (post-MI) patients with dyslipidemia (fasting serum cholesterol concentration above 240 mg/dL and triglyceride concentration above 141 mg/dL).

Results

  • Bezafibrate reduced the levels of LDL-C and triglycerides by 53% and 46% respectively
  • Plasma apolipoprotein (apo) B levels reduced by 9%
  • HDL3 levels rose by 9%

Conclusion

The effect of bezafibrate on progression of focal coronary atherosclerosis could be at least partly attributed to a rise in HDL3 cholesterol and a decrease in the total number of apo B-containing lipoproteins. Treatment with bezafibrate also significantly reduced the levels of insulin-like growth factor (IGF-1) which is one other factor associated with disease progression.[1][2][3][4]

References

  1. ↑ Ruotolo G, Ericsson CG, Tettamanti C; et al. (1998). "Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)". J. Am. Coll. Cardiol. 32 (6): 1648–56. PMID 9822092. Unknown parameter |month= ignored (help)
  2. ↑ de Faire U, Ericsson CG, Hamsten A, Nilsson J (1995). "Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)". Drugs Exp Clin Res. 21 (3): 105–24. PMID 7555614.
  3. ↑ Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U (1996). "Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients". Lancet. 347 (9005): 849–53. PMID 8622389. Unknown parameter |month= ignored (help)
  4. ↑ Ericsson CG (1998). "Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress". Eur. Heart J. 19 Suppl H: H37–41. PMID 9717064. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=BECAIT_Trial&oldid=905938"